Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies.

Personalized Medicine Using Cutting Edge Technologies for Genetic Epilepsies. Curr Neuropharmacol. 2020 Sep 15;: Authors: Garcia-Rosa S, de Freitas Brenha B, da Rocha VF, Goulart E, Silva Araujo BH Abstract Epilepsy is the most common chronic neurologic disorder in the world, affecting 1-2% of the population. Besides, 30% of epilepsy patients are drug-resistant. Genomic mutations seem to play a key role in its etiology and knowledge of strong effect mutations in protein structures might improve prediction and the development of efficacious drugs to treat epilepsy. Several genetic association studies have been undertaken to examine the effect of a range of candidate genes for resistance. Although, few studies have explored the effect of the mutations into protein structure and biophysics in the epilepsy field. Much work remains to be done, but the scene is set for exciting developments that will hold therapeutic potential for patients with drug-resistant. In summary, we provide a critical review of the perspectives for the development of individualized medicine for epilepsy based on genetic polymorphisms/mutations in light of core elements such as transcriptomics, structural biology, disease model, pharmacogenomics and pharmacokinetics in a manner to improve the success of trial designs of antiepileptic drugs. PMID: 32933463 [PubMed - as supplied by publisher]
Source: Current Neuropharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Neuropharmacol Source Type: research